Prescriptions for nerve pain medicines like Neurontin and Lyrica more than tripled in recent years, driven by increased use among chronically ill older adults and patients already taking opioids, a U.S. study suggests.

The U.S. FDA approved Merck’s and Pfizer’s Steglatro (ertugliflozin), a sodium-glucose co-transporter 2 (SGLT2)- inhibitor, which will square off against established drugs in the market.

Life expectancy in the United States dipped in 2016 as the number of deaths due to opioid drug overdoses surged and total drug overdose deaths rose 21 percent to 63,600, the U.S. Centers for Disease Control and Prevention said.

The U.S. Food and Drug Administration approved Sanofi SA’s Admelog as the first follow-on biologic version of Eli Lilly and Co.’s fast-acting insulin Humalog.

Montana sued OxyContin maker Purdue Pharma LP, withdrawing from a multistate investigation by attorneys general into opioid manufacturers’ marketing practices and joining a growing list of states that have broken off to pursue individual lawsuits.

Opioid drug abuse cost the U.S. economy as much as $504 billion in 2015, White House economists said in a report.

The billionaire founder of Insys Therapeutics Inc. appeared in federal court in Boston to plead not guilty to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug.

Sage Therapeutics Inc.’s postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the disorder.

Kentucky accused units of Endo International Plc of contributing to drug overdoses and an opioid epidemic by deceptively marketing its painkiller Opana ER, the latest lawsuit by state or local governments against the drugmaker.

Merck & Co. reported profit ahead of Street estimates on strong sales of its cancer drug Keytruda, but total revenue fell in third-quarter 2017 from disruptions due to the NotPetya cyber attack and loss of market share for many of the company’s older drugs.